Evidence map›Paper›PMID 38860398›Full record

ArticleJournal of the American Heart Association2024

Plasma Extracellular MicroRNAs Associated With Cardiovascular Disease Risk Factors in Middle-Aged and Older Adults.

Hannah Karlin, Meera Sooda, Martin Larson, Jian Rong, Tianxiao Huan, Michelle M J Mens, Frank J A van Rooij, M Arfan Ikram, Paul Courchesne, Jane E Freedman and 5 more

Abstract read
In one paragraph

Article in Journal of the American Heart Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hannah KarlinFramingham Heart Study Framingham MA USA.ORCID 0009-0009-7632-8110
Meera SoodaFramingham Heart Study Framingham MA USA.ORCID 0000-0003-3415-3147
Martin LarsonFramingham Heart Study Framingham MA USA.ORCID 0000-0002-9631-1254
Jian RongFramingham Heart Study Framingham MA USA.
Tianxiao HuanFramingham Heart Study Framingham MA USA.
Michelle M J MensDepartment of Epidemiology Erasmus MC University Medical Center Rotterdam The Netherlands.
Frank J A van RooijDepartment of Epidemiology Erasmus MC University Medical Center Rotterdam The Netherlands.ORCID 0000-0002-8600-9852
M Arfan IkramDepartment of Epidemiology Erasmus MC University Medical Center Rotterdam The Netherlands.ORCID 0000-0003-0372-8585
Paul CourchesneFramingham Heart Study Framingham MA USA.ORCID 0000-0001-5691-6913
Jane E FreedmanDepartment of Medicine, Division of Cardiovascular Medicine Vanderbilt University Medical Center Nashville TN USA.ORCID 0000-0002-0011-6164
Roby JoehanesFramingham Heart Study Framingham MA USA.ORCID 0000-0001-5549-9054
Gregory P MuellerDepartment of Anatomy, Physiology, and Genetics, F. Edward Hebert School of Medicine Uniformed Services University of the Health Sciences Bethesda MD USA.
Maryam KavousiDepartment of Epidemiology Erasmus MC University Medical Center Rotterdam The Netherlands.ORCID 0000-0001-5976-6519
Mohsen GhanbariDepartment of Epidemiology Erasmus MC University Medical Center Rotterdam The Netherlands.ORCID 0000-0002-9476-7143
Daniel LevyFramingham Heart Study Framingham MA USA.ORCID 0000-0003-1843-8724

Funding

Framingham Project/LevyZIAHL006001 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI LEVY, DANIEL · 2009 to 2025
$51.1M
FRAMINGHAM HEART STUDY - YEAR 5 EXAM75N92019D00031 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · 2019 to 2024
$29.8M
NHLBI NIH HHS 75N92019D00031
6 · The paper itself

Abstract

backgroundExtracellular microRNAs (miRNAs) are a class of noncoding RNAs that remain stable in the extracellular milieu, where they contribute to various physiological and pathological processes by facilitating intercellular signaling. Previous studies have reported associations between miRNAs and cardiovascular diseases (CVDs); however, the plasma miRNA signatures of CVD and its risk factors have not been fully elucidated at the population level. METHODS AND

resultsPlasma miRNA levels were measured in 4440 FHS (Framingham Heart Study) participants. Linear regression analyses were conducted to test the cross-sectional associations of each miRNA with 8 CVD risk factors. Prospective analyses of the associations of miRNAs with new-onset obesity, hypertension, type 2 diabetes, CVD, and all-cause mortality were conducted using proportional hazards regression. Replication was carried out in 1999 RS (Rotterdam Study) participants. Pathway enrichment analyses were conducted and target genes were predicted for miRNAs associated with ≥5 risk factors in the FHS. In the FHS, 6 miRNAs (miR-193b-3p, miR-122-5p, miR-365a-3p, miR-194-5p, miR-192-5p, and miR-193a-5p) were associated with ≥5 risk factors. This miRNA signature was enriched for pathways associated with CVD and several genes annotated to these pathways were predicted targets of the identified miRNAs. Furthermore, miR-193b-3p, miR-194-5p, and miR-193a-5p were each associated with ≥2 risk factors in the RS. Prospective analysis revealed 8 miRNAs associated with all-cause mortality in the FHS.

conclusionsThese findings highlight associations between miRNAs and CVD risk factors that may provide valuable insights into the underlying pathogenesis of CVD.

Indexed as

Cardiovascular DiseasesHeart Disease Risk FactorsMicroRNAsAgedAge FactorsBiomarkersCirculating MicroRNACross-Sectional StudiesFemaleHumansMaleMiddle AgedProspective StudiesRisk AssessmentRisk FactorsBiomarkersCirculating MicroRNAMicroRNAscardiovascular diseaseextracellular RNAmicroRNApathwaysrisk factors

Identifiers

PMID38860398
PMCPMC11255734

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.